Helio Genomics presents top abstract on methylation model for liver cancer prognosis at San Antonio symposium
Summary: Helio Genomics presented its Methylation Model Score at the 2024 San Antonio Liver Cancer Symposium, highlighting its effectiveness in assessing prognosis and treatment response in hepatocellular carcinoma (HCC) patients. The study, conducted with Ochsner Health, was recognized as one of the top three abstracts.
The research involved 108 patients with liver cirrhosis, using cell-free DNA (cfDNA) methylation biomarkers to evaluate disease aggressiveness. Helio's model outperformed established metrics in predicting patient outcomes and identifying treatment responders.
Helio's ECLIPSE platform was utilized for cfDNA analysis, enhancing the accuracy of methylation detection. This study addresses the need for reliable prognostic biomarkers in HCC, offering potential for improved patient management.
This is article metrics. Combined, they form a significance score, that indicates how important the news is on a scale from 0 to 10.
My algorithm scores 10,000 news articles daily, and creates a single significance-ordered list of news.
Read more about how I calculate significance, or see today's top ranked news on the main page:
See today's news rankings